New medical developments in the management of LUTS in adult men

Charles C. Chapple, Pierre Teillac(Hôpital Saint-Louis), Masahide Takeda, Teuvo L.J. Tammela(Tampere University), Martin C. Michel(Johannes Gutenberg University Mainz), Domenico Prezioso(Federico II University Hospital), P. Perrin, R. Berges(Ruhr University Bochum), S. A. Kaplan, Walter Artibani(University of Padua)

Pure Amsterdam UMC

January 1, 2006

Cited by 9

Related Papers

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

|Nature Genetics|2018|1k

XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors

|Pharmacological Reviews|1998|893

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

|European Urology|2016|414

Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia

|The Lancet|1995|290

Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group

|Archivio Italiano di Urologia e Andrologia|2015|202